nm23-H1 Expression and Ovarian Cancer Prognosis
Author Information
Author(s): Schneider J, Pollán M, Jiménez E, Marenbach K, Martínez N, Volm M, Marx D, Meden H
Primary Institution: Departamento de Especialidades Médico-Quirúrgicas, Universidad del País Vasco, Bilbao, Spain
Hypothesis
Does nm23-H1 expression affect the prognosis of patients with early-stage epithelial ovarian carcinoma?
Conclusion
Higher nm23-H1 expression is linked to lower survival rates in early-stage epithelial ovarian carcinoma patients.
Supporting Evidence
- Patients with higher nm23-H1 expression scores had significantly lower survival rates.
- The effect was mainly seen in early-stage, well- and moderately differentiated tumors.
- Nm23-overexpression was identified as the only significant independent predictor of poor prognosis.
Takeaway
If a patient has a certain gene that is more active, they might not live as long if they have early-stage ovarian cancer.
Methodology
The study involved immunohistochemistry and a semiquantitative scoring system to assess nm23-H1 expression in tumor samples.
Potential Biases
Potential bias in patient selection and follow-up duration.
Limitations
The study's findings may not apply to all ovarian cancer patients, as it focused on a specific subgroup.
Participant Demographics
Patients with early-stage (I and II), well- and moderately differentiated epithelial ovarian carcinoma.
Statistical Information
P-Value
0.01
Statistical Significance
p=0.01
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website